The FDA based its approval of pembrolizumab on findings from the phase 2 KEYNOTE-158 trial.
Commentary|Articles|September 4, 2024
- ONCOLOGY Vol 38, Issue 10
- Volume 38
- Issue 10
- Pages: 372-374
Cancer Rehabilitation Medicine: “Bridging the Gap” With Supportive Care
Author(s)Ariana Pelosci
Fact checked by: Russ Conroy
Cancer rehabilitation medicine may help bridge a gap in oncology care, according to Jessica Cheng, MD.
Advertisement
Advertisement
Finding ways to improve quality of life outcomes is always a goal for oncologists. Those in the emerging field of cancer rehabilitation medicine have the opportunity to bridge a gap in oncology care.
Related to this article
Industry payments to oncologists were associated with greater use of the promoted treatment, whether or not it was guideline-preferred for the patient’s cancer.
Hope S. Rugo, MD, FASCO, and Irene M. Kang, MD, discussed ASCENT-03, -04, and TROPION-Breast02 data, sequencing, and toxicity in metastatic TNBC.
Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.
Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.
Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.
Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.
Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.
Advertisement
Advertisement